- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04498377
Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Multicenter Study to Evaluate the Efficacy and Safety of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19
Study Overview
Detailed Description
The study is planned to include 4 cohorts, with enrolled patients being randomized 1:1 in a blinded manner on Day 1, following screening, to F-652 or placebo as follows:
- Cohort 1 (sentinel cohort): Four patients will receive either dose level 1 F-652 or placebo. Upon completion of sentinel, the Data Monitoring Committee will evaluate the safety and tolerability data of the sentinel patients and determine if it is acceptable to dose the remaining patients in this dosing group in Cohort 2.
- Cohort 2: Fourteen patients will receive either dose level 1 F-652 or placebo. Upon completion of Cohort 2, the DMC will convene and review all available safety data to determine if the study can proceed to the next dose level.
- Cohort 3 (sentinel cohort): Four patients will receive either dose level 2 F-652 or placebo. Upon completion of sentinel dosing, the DMC will evaluate the safety and tolerability data of the sentinel patients and determine if it is acceptable to dose the remaining patients in this dosing group in Cohort 4.
- Cohort 4: Sixteen patients will receive either dose level 2 F-652 or placebo. Treatment will begin on Day 1 following randomization. Patients assigned to active drug will receive a total of 2 doses of F-652 (1 IV infusion on Day 1 and 1 IV infusion on Day 8). Patients assigned to placebo will receive identical IV infusions of placebo vehicle on Days 1 and 8. All patients will receive available supportive and antiviral therapies as standard of care. Efficacy will be assessed on Days 15 and 29. Patients will be followed for safety until Day 60.
The primary efficacy endpoint is the proportion of patients with a ≥2-point increase in the National Institute of Allergy and Infectious Diseases (NIAID) 8-point ordinal scale from baseline to Day 29.
The secondary efficacy endpoints include the proportion of patients with a ≥2-point increase in the NIAID 8-point ordinal scale from baseline to Day 15, mortality rate by Days 15 and 29, percentage of patients who have recovered and discharged from the hospital by Days 15 and 29, and percentage of patients progressed to severe/critical disease by Day 15.
The safety endpoints include all cause treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs); change from screening (baseline) in clinical symptoms and abnormal vital signs, abnormal laboratory tests; and relationship of any AEs with F-652 treatment.
The exploratory endpoints include time to negative SARS-CoV-2 PCR test from randomization; and changes in pharmacodynamic parameters.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70112
- Tulane University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Willing to provide informed consent and able to comply with protocol requirements
- 18 years or older
- Has a COVID-19 diagnosis confirmed by PCR
- Hospitalized within 5 days and meets the following criteria at screening:
Peripheral capillary oxygen saturation (SpO2) ≤ 93% on room air or SpO2 ≥93% on ≤10 liters per minute of supplemental oxygen via nasal cannula
- Radiographic (chest X-ray, computed tomography scan, or ultrasound) evidence of bilateral pulmonary infiltrates consistent with SARS-CoV-2/COVID-19
- Clinical symptoms consistent with COVID-19 per Investigator judgement
- Body mass index between 18 to 40 kg/m2
- If of reproductive potential, willing to abstain or agree to the use of highly effective contraception
Exclusion Criteria:
- Respiratory failure at screening
- History of heart failure
- History of COPD or bronchial asthma
- Active TB or history of TB of the following types
- Uncontrolled arrhythmia within 3 months prior to randomization
- Heart disease of the following types
- Moderate to severe renal insufficiency
- Abnormal white cell and platelet counts
- History of transplantation of vital organs (e.g., heart, lung, liver, and/or kidney);
- Malignant tumor
- Uncontrolled systemic or local autoimmune or inflammatory disease besides SARS-CoV-2
- Unhealed wounds, active gastric ulcer, had surgery
- Received other investigational therapeutic products
- Used interferon therapies
- History of HIV infection, hepatitis B, and/or hepatitis C
- Known serious allergic reaction or hypersensitivity to components of F-652
- Pregnant or breastfeeding
- History of drug abuse or use of narcotics
- Treated with immunomodulators or immunosuppressants
- Other conditions resulting in increased risk
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: F-652
Patient receives standard care plus F-652
|
IL-22 fusion protein administered intravenously
|
Placebo Comparator: Placebo
Patient receives standard care plus placebo
|
Placebo administered intravenously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NIAID 8-point Ordinal Scale
Time Frame: Study day 1 before dose to day 29
|
The proportion of patients with a greater or equal 2-point change in the National Institute of Allergy and Infectious Diseases (NIAID) 8-point ordinal scale from baseline to Day 29. The NIAID 8-point ordinal scale includes the following grades:
|
Study day 1 before dose to day 29
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Christine M Bojanowski, MD, Tulane University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GC-652-04
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichEnrolling by invitation
-
Alexandria UniversityCompleted
Clinical Trials on F-652
-
Mayo ClinicVirginia Commonwealth University; Indiana University; Hennepin County Medical...Completed
-
EVIVE BiotechnologyWithdrawn
-
Tobira Therapeutics, Inc.Completed
-
AbbottCompleted
-
EVIVE BiotechnologyMemorial Sloan Kettering Cancer CenterCompletedAcute Graft vs Host DiseaseUnited States
-
University of ArkansasErasmus Medical Center; The Netherlands Cancer Institute; Biolitec Pharma Ltd.TerminatedSquamous Cell Carcinoma of the Head and NeckUnited States
-
University of Kansas Medical CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
AbbVie (prior sponsor, Abbott)TerminatedDiabetic Neuropathic PainUnited States
-
Chengdu PLA General HospitalUnknown
-
Clinique Romande de ReadaptationRecruitingHand Injuries and DisordersSwitzerland